AOD9604 peptide
AOD9604 is a synthetic peptide derived from a fragment of human growth hormone (hGH). It has been studied for its potential role in fat metabolism and weight regulation, although it has not been approved as a medicine for obesity or metabolic diseases.
AOD9604 peptide was originally developed by Metabolic Pharmaceuticals as a potential therapy targeting metabolic pathways involved in fat breakdown. Unlike full growth hormone, AOD9604 was designed to retain only the region believed to influence lipolysis (fat breakdown) while avoiding effects related to growth hormone signaling.
How AOD9604 peptide works
AOD9604 corresponds to a small fragment of human growth hormone, sometimes referred to as hGH fragment 176–191. Laboratory research suggests that this peptide may influence metabolic pathways associated with fat metabolism. Potential mechanisms studied in research include:
stimulating lipolysis, the breakdown of stored fat in adipose tissue
inhibiting lipogenesis, the formation of new fat cells
influencing metabolic signaling pathways involved in energy balance
Importantly, AOD9604 was designed to avoid direct activation of the growth hormone receptor, which means it does not appear to produce the typical endocrine effects associated with growth hormone therapy.
Because of this selective design, researchers investigated whether the peptide could influence body fat without affecting growth hormone–related pathways.
Clinical trials and evidence
AOD9604 peptide has been evaluated in several clinical studies investigating its potential effects on weight loss and fat metabolism.
Early trials examined the peptide in individuals with obesity, measuring changes in body weight and metabolic parameters. Some studies reported modest effects on fat metabolism, while others found limited differences compared with placebo.
Overall, the available clinical evidence has been mixed, and the peptide did not progress to widespread pharmaceutical approval as a treatment for obesity.
Research has also explored AOD9604 in other contexts, including cartilage regeneration and osteoarthritis models, although these applications remain experimental.
Possible side effects of AOD9604 peptide:
Clinical studies evaluating AOD9604 generally reported a relatively favorable safety profile, with side effects occurring at rates similar to placebo in several trials. Reported side effects have included:
headache
mild gastrointestinal discomfort
injection site reactions
Because the peptide was designed to avoid growth hormone receptor activation, studies did not observe typical hormonal side effects associated with growth hormone therapy.
However, the long-term safety of AOD9604 outside controlled research settings has not been fully established.
References:
– Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans, Stier et al., 2013 – Journal of Endocrinology and Metabolism, https://jofem.org/index.php/jofem/article/view/157/194
– The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism…, Heffernan et al., 2001 – Endocrinology, https://academic.oup.com/endo/article-abstract/142/12/5182/2988749
– AOD9604, an orally active peptide for the treatment of obesity, Wittert et al., 2005 – Diabetes (Phase 2b), https://www.regulations.gov/comment/FDA-2024-N-4777-0009